Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

Inclusion Criteria: * Histologically document transitional cell carcinoma with the presence of any of the following stages: carcinoma in situ (CIS), high-grade Ta, or any grade T1, detectable at the time of study accrual; combinations of the aforementioned stages are acceptable; subjects with mixed histology are required to have a dominant transitional cell carcinoma (TCC) pattern * Failure of prior intravesical treatment(s), one of which must include a course of BCG; failure is defined as evidence of TCC on cystoscopic examination and biopsy or cystoscopic examination and urine cytology at least 6 weeks from completion of last treatment * Patient is either ineligible for or declines radical cystectomy; the investigator must explain that a delay in cystectomy may increase the patient?s chance of disease progression * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Ability to understand and willingness to sign written informed consent * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \< 2.5 x institutional upper limit of normal (ULN) and total bilirubin \< 1.5 x institutional ULN * Absolut neutrophil count (ANC) \> 1500/uL * Platelets \>= 75,000/uL * Hemoglobin \> 8 mg/dL without need for hematopoetic growth factor or transfusion support * Estimated glomerular filtration rate (GFR) \> 30 ml/min * Serum creatinine less than 1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance = or 60 mL/min for subject with creatinine levels …